Skip to main content
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
New — The Peptide Dictionary: 128 terms, explained simply
New guide — NAD+ for Anti-Aging: What the Science Says
New guide — GHK-Cu: the copper peptide for your skin
Not sure where to start? — A 60-second quiz points you to the path that fits your goal
New explainer — Semaglutide: what the research says, made simple
Browse — Peptide guides, made simple
Easy-to-follow guides
Independent reviews
Vetted providers
Free to read

Home / Peptide legality / Vermont

Peptide legality · Vermont · updated 2026-09-21

Are peptides legal in Vermont?

Gray area

In Vermont, peptides are governed almost entirely by the federal compounding framework, so brand-name GLP-1 medicines are fully legal by prescription while most standalone research peptides sit in a regulatory gray zone.

Legal status overview

Vermont follows the federal compounding framework, which means brand-name GLP-1 medicines are legal by prescription while most standalone research peptides remain in a gray zone. The Vermont Board of Pharmacy has not published a peptide-specific rule, so pharmacies default to the federal floor set by the FDA and sections 503A and 503B. Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved and legally prescribed, while compounded copies narrowed sharply after the FDA declared the semaglutide shortage resolved in February 2025. Research peptides such as BPC-157 and TB-500 are neither scheduled nor FDA-approved, leaving their human use unsettled. This is information, not medical or legal advice.

Key points

  • Vermont has no peptide-specific Board of Pharmacy statement, so pharmacies operate under the federal compounding floor set by the FDA and sections 503A and 503B. [3]
  • Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved and legal to prescribe in Vermont; the legality questions center on compounded versions, not the branded products. [1]
  • After the FDA declared the semaglutide shortage resolved in February 2025, 503A pharmacies can no longer routinely compound copies of the branded drug, with enforcement discretion ending in the spring of 2025. [1]
  • Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA, and may be prepared only for a documented patient-specific clinical need. [6]
  • BPC-157 was removed from FDA Category 2 of the 503A bulk substances list in April 2026 and recommended for the 503A list by the advisory committee in July 2026, but it is not yet permitted pending final rulemaking. [4]
  • A Vermont-licensed provider prescribing by telehealth must hold the appropriate license and document the clinical basis, consistent with state telemedicine rules. [2]
  • Research peptides sold 'for research use only' are unscheduled but are not authorized for human use, a distinction that applies in Vermont as elsewhere. [5]

Compound-by-compound status

BPC-157
Gray area
Not FDA-approved and not a controlled substance; removed from 503A Category 2 in April 2026 and recommended for 503A in July 2026, but not yet permitted for compounding pending final FDA rulemaking.
GLP-1 class: Wegovy® (semaglutide) and Zepbound® (tirzepatide)
Restricted
Branded products are FDA-approved and legal by prescription; compounded semaglutide and tirzepatide are not FDA-approved, are not a generic, and have not been evaluated by the FDA, and are permitted only for a documented patient-specific clinical need after the 2025 shortage resolution.
TB-500 (thymosin beta-4 fragment)
Restricted
Not FDA-approved and not on the permitted 503A bulk substances list; marketed only as a research chemical and not authorized for human use.
Growth hormone / somatropin
Restricted
FDA-approved by prescription for defined indications; federal law (21 U.S.C. 333(e)) makes distribution or possession for non-approved uses a crime, so it is tightly restricted rather than freely available.

Frequently asked questions

Is compounded semaglutide legal in Vermont?

It can be legal when a Vermont-licensed prescriber documents a patient-specific clinical reason and a licensed 503A pharmacy prepares it, but routine compounding of copies of Wegovy® (semaglutide) ended after the FDA declared the shortage resolved in February 2025. Compounded semaglutide is not FDA-approved, is not a generic, and has not been evaluated by the FDA.

Is BPC-157 legal in Vermont?

BPC-157 is not a controlled substance in Vermont, but it is not FDA-approved and is not currently permitted for pharmacy compounding, so it remains in a gray zone. Products sold 'for research use only' are not authorized for human use.

Does Vermont have its own peptide law?

Vermont has not issued a peptide-specific Board of Pharmacy rule, so the federal framework under the FDA and sections 503A and 503B controls.

Can I get peptides through telehealth in Vermont?

A provider prescribing by telehealth must be appropriately licensed and must document a clinical basis, and any compounded product still has to meet federal compounding limits.

Are brand-name GLP-1 medicines legal in Vermont?

Yes. Wegovy® (semaglutide) and Zepbound® (tirzepatide) are FDA-approved and legally prescribed; the legal uncertainty applies to compounded and research peptides.

General information based on the sourced research above, not legal advice. For a specific situation in Vermont, consult a licensed attorney familiar with pharmaceutical law.